PROTECT AF
2014
Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation
In 707 patients with non-valvular atrial fibrillation eligible for warfarin, Watchman left atrial appendage closure was non-inferior for stroke, systemic embolism, or cardiovascular death compared with warfarin.
Result
Efficacy: Composite of stroke, cardiovascular/unexplained death, and systemic embolismrate ratio 0.60 (95% CI 0.41-1.05)
Below 1 favours Watchman left atrial appendage closure, above 1 favours warfarin.
Also reported: At mean 3.8-year follow-up, LAA closure met both non-inferiority and superiority vs warfarin ( ; superiority probability 96%). Original 2009 report showed non-inferiority.
- Subtopic
- LAAO
- Design
- Open-label non-inferiority RCT (2:1 device:warfarin)
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2024 AFACC/AHA 2023 AF
- Source
- Reddy VY, et al. JAMA. 2014;312(19):1988-1998.doi 10.1001/jama.2014.15192
Discussion & critique
Early benefit offset by frequent procedural complications (pericardial effusion), and the warfarin comparator predates DOACs. Established percutaneous LAA closure as an alternative to warfarin and led to Watchman approval.